<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090397</url>
  </required_header>
  <id_info>
    <org_study_id>STU00213826</org_study_id>
    <nct_id>NCT05090397</nct_id>
  </id_info>
  <brief_title>MRI-Guided High-Definition Transcranial Direct Current Stimulation (tDCS) for Depression</brief_title>
  <official_title>Applied Strategies for MRI-Guided High-Definition tDCS for Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to understand how a neurostimulation technique, transcranial&#xD;
      electrical stimulation (tES), affects brain function in adults with major depression measured&#xD;
      with functional magnetic resonance imaging (fMRI). This study targets a specific kind of tES&#xD;
      called transcranial direct current stimulation (tDCS), where a mild, constant current is&#xD;
      passed between electrodes placed on the scalp.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator-initiated MRI research study of a noninvasive neurostimulation&#xD;
      technique, transcranial direct current stimulation (tDCS) using focal &quot;high definition&quot; (HD)&#xD;
      electrodes positioned using pre-treatment MRI. Primary objective is to measure changes in&#xD;
      brain function during MRI-guided HDtDCS with MRI. Secondary objective is to measure changes&#xD;
      in depressive symptoms after five consecutive days of MRI-guided tDCS (20 minutes per&#xD;
      session).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in brain functional connectivity</measure>
    <time_frame>Acute/immediate</time_frame>
    <description>Functional MRI will measure changes in brain function during tDCS. Specifically, the investigators will measure change in functional connectivity of prefrontal cortex (% change in Fisher's z).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in depressive symptoms (Hamilton)</measure>
    <time_frame>1 week, 2 weeks, 1 month</time_frame>
    <description>Symptoms of depression will be measured before and after 5 sessions of tDCS using Hamilton Depression Rating Scale (HDRS 17-item). Change HDRS score will be used as a secondary outcome measure. Score range is 0-53, where low scores indicate low symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in depressive symptoms (Beck)</measure>
    <time_frame>1 week, 2 weeks, 1 month</time_frame>
    <description>Symptoms of depression will be measured before and after 5 sessions of tDCS using Beck Depression Inventory (BDI). Change BDI score will be used as a secondary outcome measure. Score range is 0-62, where low scores indicate low symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation</intervention_name>
    <description>Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Transcranial Direct Current Stimulation</intervention_name>
    <description>Sham Transcranial Direct Current Stimulation</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Ages between 18 and 65&#xD;
&#xD;
          -  2. Race/ethnicity: all races and ethnic groups&#xD;
&#xD;
          -  3. Sex/Gender: all&#xD;
&#xD;
          -  4. Capacity to provide informed consent&#xD;
&#xD;
          -  5. Diagnosis of Major Depressive Disorder made by volunteer's physician at least one&#xD;
             year prior (confirmed by patient self-report)&#xD;
&#xD;
          -  6. Currently under the care of a clinician for depression (psychiatrist, psychologist,&#xD;
             or other clinician)&#xD;
&#xD;
          -  7. Currently experiencing symptoms of depression (Patient Health Questionnaire 9, PHQ9&#xD;
             &gt;4 at screening; Hamilton Depression Rating Scale 17-item, HDRS-17, score &gt;8 at Visit&#xD;
             1)&#xD;
&#xD;
          -  8. Stable or no pharmacological antidepressant regimen (SSRI, SNRI, MOAI, or&#xD;
             tricyclic/TCA) with no change in treatment 6 weeks prior to study start&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Ages below 18 (neurobiology is quite different in children vs. adults)&#xD;
&#xD;
          -  2. Ages above 65 (cortical excitability changes with age)&#xD;
&#xD;
          -  3. Active suicidal thoughts, ideation, or behavior with plan within the past month&#xD;
             (HDRS-17 item 3 score 3-4)&#xD;
&#xD;
          -  4. Change in antidepressant medication within 6 weeks of study start&#xD;
&#xD;
          -  5. Diagnosis of any medical condition potentially affecting brain function:&#xD;
             neuropsychiatric or mental disorders, other mood disorders (bipolar disorder, primary&#xD;
             anxiety disorder, PTSD), psychotic states or disorders, developmental disorders,&#xD;
             neurological disorders, including mild cognitive impairment, significant head injury,&#xD;
             significant history of alcohol/substance abuse or dependence within past 12 months,&#xD;
             chronic pain (current, or for more than one year within the past one year), other&#xD;
             major medical conditions (e.g., cancer, stroke).&#xD;
&#xD;
          -  6. MRI contraindications: metal or other implants that are not MR-safe,&#xD;
             claustrophobia, pregnancy or suspected pregnancy&#xD;
&#xD;
          -  7. tES contraindications: skin conditions or injuries on the scalp hair extensions,&#xD;
             wigs, braids, etc. that cannot be removed prior to the study, metal implants or&#xD;
             pacemakers (also contraindicated for MRI)&#xD;
&#xD;
          -  8. Non-English speakers (due to written consent and questionnaires administered)&#xD;
&#xD;
          -  9. Neurostimulation or neuromodulation treatment for any reason within the past 3&#xD;
             months&#xD;
&#xD;
          -  10. Current medication use potentially affecting brain function, including&#xD;
             decongestants, antihistamines, benzodiazepines or other anticonvulsants,&#xD;
             anti-psychotics.&#xD;
&#xD;
          -  11. Prisoners will not participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Amber Leaver</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

